Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS
2017-002754-36Phase 3Completed
- Sponsor
- Orion Corporation
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Oral levosimendan with Placebo (2 arms). Primary endpoint: Supine slow vital capacity (SVC) %. Started Jan 2018; status: completed.
02
Drugs
levosimendan
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2017-002754-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002754-36.